Abeona Posts Q2 Profit on Asset Sale
Abeona Therapeutics (NASDAQ:ABEO), a biotechnology company focused on developing and commercializing cell and gene therapies for rare diseases, reported its second quarter 2025 earnings on August 14, 2025. The biggest news from the release is a notable positive net income (GAAP) for Q2 2025, driven entirely by a one-time asset sale, while the first commercial product launch remains on the horizon. For Q2 2025, the company delivered GAAP earnings per share of $1.71, beating analyst estimates of a $(0.39) loss, and reported $0.4 million in GAAP revenue, both above expectations. However, both figures reflect non-recurring activities rather than regular operations. Management described the quarter as a transition point, showing strength in its regulatory achievements and readiness for commercialization, but with future performance hinging on successful sales of its first approved therapy.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q3 2025 earnings report.
Abeona Therapeutics is a commercial-stage biotech focused on developing cell and gene therapies for severe and rare diseases. Its portfolio centers around ZEVASKYN, an autologous cell-based gene therapy, recently approved for treating wounds in recessive dystrophic epidermolysis bullosa (RDEB). This condition causes persistent skin wounds and is classified as a rare and life-threatening disease.
Source Fool.com
